Connect with us

Hi, what are you looking for?

Jewish Business News

VC, Investments

Israeli startup, Alpha TAU Medical, plans to kill tumors from within

Tow Israeli MedTech companies raised funds those days: Alpha TAU has raised 26 million round B, and Curesponse raised $5 million.

Israeli MedTech startup Alpha TAU Medical, which uses Alpha ray technology to kill solid cancer tumors from within, has raised 26 million Series B investment led by existing investors, OurCrowd, Shavit Capital, and Madison Ventures alongside new investors from Israel and North America.

Founded in 2016 by two Tel Aviv University professors, CSO Prof. Yona Keisar and CPO Prof. Itzhak Kelson, who both invented the company’s DaRT technology in 2003. Alpha TAU Medical has raised $55 million to date.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

The funds will go for building production centers in Israel and abroad, as well as towards receiving a CE quality standard stamp attesting compatibility to market in EU countries.

Alpha TAU uses Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) to insert the seeds directly into the tumor, releasing a small amount of radioactive substance, called Radium-224, over a range of a few millimeters, without contaminating the surrounding tissue, allowing for secure treatment of the tumor itself. Radium-224’s short half-life, about 3.7 days, allows for a quick and minimally invasive treatment that kills the tumor from within.

Over the last year, Alpha TAU Medical has completed a series of clinical trials in people in Israel and Italy to treat Squamous Cell Carcinoma (SCC). Additionally, the company is performing further clinical trials in other places around the world, including first trial in a U.S. medical center and a center specializing in pancreatic cancer, in Montreal.

“The funds will assist us in our mission to help cancer patients even in these challenging times when the medical focus is mostly on the COVID-19 virus,” said CEO, Uzi Sofer.
Another Israeli MedTech company, Curesponse, has raised $6 million from Marius Nacht’s fund aMoon and from British NCL Technology Ventures. Curesponse has developed a 3-dimensional tissue culture system for modeling cancer growth and drug response. The company has also created tumors for Pharma companies that want to test treatments on specific kinds of tumors.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.